BDBM50221553 4-(7-(2-chloro-5-hydroxyphenyl)-5-methylbenzo[e][1,2,4]triazin-3-ylamino)-N-(2-(pyrrolidin-1-yl)ethyl)benzenesulfonamide::4-{[7-(2-chloro-5-hydroxyphenyl)-5-methyl-1,2,4-benzotriazin-3-yl]amino}-N-(2-pyrrolidin-1-ylethyl)benzenesulfonamide::CHEMBL249821::US8481536, 463::US8481536, 603

SMILES Cc1cc(cc2nnc(Nc3ccc(cc3)S(=O)(=O)NCCN3CCCC3)nc12)-c1cc(O)ccc1Cl

InChI Key InChIKey=ZBRROTSBDAODQD-UHFFFAOYSA-N

Data  1 KI  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 50221553   

TargetEphrin type-B receptor 4(Homo sapiens (Human))
Targegen

US Patent
LigandPNGBDBM50221553(4-(7-(2-chloro-5-hydroxyphenyl)-5-methylbenzo[e][1...)
Affinity DataIC50:  30.8nMT: 2°CAssay Description:Testing of inhibition of kinases in vitro using luciferase-based assay from KinaseGlo, Promega Corp.More data for this Ligand-Target Pair
In DepthDetails US Patent